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Abstract The yeast ERG4 gene encodes sterol C-24(28)
reductase which catalyzes the final step in the biosynthesis of
ergosterol. Deletion of ERG4 resulted in a complete lack of
ergosterol and accumulation of the precursor ergosta-
5,7,22,24(28)-tetraen-3L-ol. An erg4 mutant strain exhibited
pleiotropic defects such as hypersensitivity to divalent cations
and a number of drugs such as cycloheximide, miconazole,
4-nitroquinoline, fluconazole, and sodium dodecyl sulfate.
Similar to erg6 mutants, erg4 mutants are sensitive to the
Golgi-destabilizing drug brefeldin A. Enzyme activity measure-
ments with isolated subcellular fractions revealed that Erg4p is
localized to the endoplasmic reticulum. This view was confirmed
in vivo by fluorescence microscopy of a strain expressing a
functional fusion of Erg4p to enhanced green fluorescent protein.
We conclude that ergosterol biosynthesis is completed in the
endoplasmic reticulum, and the final product is supplied from
there to its membranous destinations.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Sterols are essential components of eukaryotic cells. They
are important membrane constituents, regulating membrane
£uidity and permeability [1^4], but also speci¢cally interact
with proteins and thus modulate their activity. Sterols of high-
er eukaryotes are precursors of steroid hormones which are
involved in many di¡erent cellular processes (for a review see
[5]). The major sterol of yeast, ergosterol, is structurally and
functionally related to sterols of higher eukaryotes. Ergosterol
is synthesized through a complex pathway involving numer-
ous enzymatic steps for all of which the structural genes have
been cloned (for a review see [6]). The ¢nal step of this bio-
synthetic sequence is catalyzed by sterol C-24(28) reductase
(Fig. 1), encoded by the ERG4 gene (systematic ORF name
YGL022W). Expression of Erg4p was shown to be non-essen-
tial for cell viability [7,8], and deletion of the gene does not
result in sterol auxotrophy [9] or other auxotrophic require-
ments on complex glucose containing media.
Ergosterol synthesis is thought to be a process occurring in
the endoplasmic reticulum [10], although some enzymes of the
pathway have not yet been unambiguously localized. Re-
cently, some Erg proteins in yeast were shown to be localized
to both the endoplasmic reticulum and the lipid particle frac-
tion [11]. Lipid particles are a distinct subcellular compart-
ment which consists of a hydrophobic core containing triacyl-
glycerols and steryl esters [12] and a surface phospholipid
monolayer harboring a small amount of characteristic pro-
teins. Among these proteins [13] three enzymes involved in
sterol metabolism, squalene epoxidase, Erg1p [11], sterol
v24-methyltransferase, Erg6p [12], and lanosterol synthase,
Erg7p (Balliano et al., manuscript in preparation) were iden-
ti¢ed. Erg6p and Erg7p are abundant in lipid particles, and
only minor quantities of these enzymes were detected in the
endoplasmic reticulum. In contrast, the major location of
Erg1p [11,14] is the endoplasmic reticulum.
The presence of some sterol biosynthetic enzymes in lipid
particles suggests an active contribution of this organelle to
cellular sterol synthesis and perhaps to the regulation of the
£ux of intermediates through the pathway. Thus, it was of
interest to investigate the subcellular distribution of further
enzymes of sterol synthesis that had not previously been lo-
calized. In this report, we describe the analysis of sterol
C-24(28) reductase, Erg4p, which catalyzes the conversion of
ergosta-5,7,22,24(28)-tetraen-3L-ol to ergosterol, the ¢nal step
of the sterol biosynthetic pathway in yeast. We describe the
phenotypic consequences of a lack of Erg4p function and the
subcellular distribution of the enzyme, based on activity mea-
surements in subcellular fractions in vitro and microscopic
inspection of a functional fusion to green £uorescent protein
(GFP) in vivo.
2. Materials and methods
2.1. Strains and culture conditions
The wild-type yeast strain Saccharomyces cerevisiae W303D
(MATa/K ura3-1/ura3-1 leu2-3,112/leu2-3,112 trp1-1/trp1-1 his3-
11,15/his3-11,15 ade2-1/ade2-1 can1-100/can1-100) and the mutant
strains DZW224 (W303; MATa/K, erg4v : :URA3/ERG4 ura3-1/ura3-
1) and DZW244 (W303; MATa, erg4v : :URA3), which was derived
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Fig. 1. Enzymatic reaction catalyzed by Erg4p.
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by sporulation and tetrad dissection from DZW224, were used
throughout this study. Strain RH4217 (MATa erg4: :URA3 his4
leu2 lys2 ura3 bar1) was provided by H. Riezmann, Biocenter Basel,
Switzerland, and erg6 mutant FKY212 (MATa erg6v ura3-1 leu2-
3,112 his3-11,15 trp1-1 ade2-1 can1-100) was obtained from F. Kepes,
Gif-sur-Yvette, France. For preparation of lipid cells and subcellular
fractionation cells were grown aerobically in 2 l Erlenmeyer £asks to
the late exponential phase at 30‡C in YPD medium containing 1%
yeast extract (Oxoid), 2% peptone (Oxoid) and 2% glucose (Merck).
500 ml of culture medium was inoculated with 0.3 ml of a preculture
grown aerobically at 30‡C for 48 h. Growth was monitored by mea-
suring the optical density at 600 nm. Sporulation media were as de-
scribed by Sherman et al. [15].
Transformants harboring plasmids encoding Erg4p^EGFP fusions
were grown on uracil-free minimal medium (3URA) containing
0.67% yeast nitrogen base and 1% glucose supplemented with all
amino acids and bases, except uracil. For derepression of the
MET25p promoter (see below) cells were harvested from 3URA me-
dium and resuspended in minimal medium lacking uracil and methio-
nine (3URA, 3MET).
Growth tests were carried out on YPD media plates containing 2%
Bacto agar (Difco). Drugs, cations or detergents were added at var-
ious concentrations as indicated. Cells were pre-grown to the mid
exponential phase in liquid media, diluted with YPD to an OD600nm
of 1, 0.1 and 0.01 and spotted onto the plates.
Escherichia coli XL-Blue (Stratagene) served as the host for plas-
mids used in this study. Transformed XL-Blue strains were grown in
LB liquid medium (0.5% yeast extract, 1% tryptone, 0.5% NaCl) con-
taining 100 mg/l ampicillin (United States Biochemicals).
2.2. Isolation of yeast subcellular fractions
Yeast spheroplasts and mitochondria were isolated following pub-
lished procedures [16]. The 40 000Ug microsomal fraction was pre-
pared from the post-mitochondrial supernatant [17]. Vacuoles and
highly puri¢ed yeast lipid particles were prepared as described by
Leber et al. [12], and plasma membrane was prepared by the method
of Serrano et al. [18].
2.3. Construction of an erg4 deletion strain
The plasmid pCM2 (kindly provided by C. Marcireau, Centre de
Recherche de Vitry-Alfortville), an 11 664 bp construct with a 685 bp
fragment of ERG4 replaced by a URA3 cassette, was used for deletion
of the ERG4 gene. pCM2 originates from vector pA-B6.5 [19] which
carries an 8784 bp DNA fragment of chromosome VII including
ERG4. For construction of pCM2 and deletion of ERG4 a 685 bp
SnaBI/AvrII fragment was replaced by a 2729 bp URA3 cassette
£anked by direct repeats. A 6937 bp ERG4 gene disruption cassette
was obtained by cleaving pCM2 with SacI and HpaI. The linear DNA
was transformed into diploid W303 using the high e⁄ciency lithium
acetate transformation protocol [20] and stable uracil prototrophic
transformants were isolated. Sporulation and tetrad analysis of the
Ura transformants were carried out by standard techniques [15] and
yielded four viable spores and the uracil prototrophic marker segre-
gated 2 :23, indicating that ERG4 is not essential for vegetative
growth [7,8]. Deletion of ERG4 was con¢rmed by Southern hybrid-
ization in diploid transformants and the resulting segregants. The
URA3 gene used for gene disruption/selection was eliminated by intra-
chromosomal recombination through the £anking direct repeats by
replicating yeast on complete medium containing 5-£uoroorotic acid
(0.1%) [21].
2.4. Construction of an ERG4^EGFP fusion
1440 bp of the coding region of ERG4 including 24 bp upstream of
the ATG were ampli¢ed by PCR using genomic DNA of strain
W303D as the template. The PCR primers P1 and P2 (Fig. 2) used
for the ampli¢cation were generated such to introduce XbaI (5P-end)
and BamHI (3P-end) restriction sites for subsequent subcloning into
GFP fusion vectors, and also to replace the stop codon in order to
obtain an in-frame GFP fusion. The PCR fragment was cut with XbaI
and BamHI and introduced into the respective sites of the yeast CEN
vector pGFP-C-FUS (kindly provided by J. Hegemann, Heinrich-
Heine-Universita«t Du«sseldorf, Germany), which led to the formation
of a C-terminal GFP fusion. This vector contains the yeast MET25p
promoter that allows regulated expression of ERG4 under conditions
of methionine depletion. The correct sequence of the construct was
con¢rmed by DNA sequencing. For enhanced £uorescence of the
fusion protein the MET25p^ERG4 fragment was subcloned as BamHI
fragment (1863 bp) (primers P2 and P3, see Fig. 2) into the respective
sites of plasmid pRS416 harboring the coding region of enhanced
GFP (EGFP) in its EcoRI site (kindly provided by L. Robinson,
Department of Biochemistry and Molecular Biology, Louisiana State
University Medical Center, Shreveport, Louisiana, USA).
The plasmid encoding Erg4p^EGFP was transformed into an erg4
deletion strain using the lithium acetate method [22], and transform-
ants were selected for uracil prototrophy on synthetic media lacking
uracil. Transformation of E. coli XL1-Blue (Stratagene) was per-
formed by the CaCl2 method [23].
2.5. Fluorescence microscopy
Yeast cells were grown overnight in liquid media lacking uracil. For
derepression of MET25p-controlled gene expression cells were inocu-
lated into minimal media lacking uracil and methionine. After various
periods of time 1 ml aliquots were withdrawn and cells were concen-
trated by centrifugation at 1000 rpm (600Ug) for 2 min. Preparation
of cells for microscopic inspection and confocal microscope set-up
were as described previously [24]. GFP £uorescence was observed
by laser scanning confocal microscopy on a Leica TCS 4D confocal
microscope, using the 488 nm excitation line (Ar/Kr laser), a TK500
beam splitter and a TK525/50 band pass ¢lter for GFP £uorescence
detection.
2.6. Lipid analysis
For the analysis of total sterols the wild-type strain W303D and
erg4 mutant cells were grown in YPD for 24 h, harvested and washed
with distilled water. Cells (approximate 300 mg wet weight) were
taken up in 1.5 ml methanol, 1 ml of 0.5% pyrogallol and 1 ml of
60% KOH, and heated for 2 h at 85‡C to hydrolyze steryl esters.
Hydrolysates were extracted three times with 3 ml light petroleum
each, and the organic phases were combined and taken to dryness
under a stream of nitrogen. Lipids were dissolved in a small volume
of cyclohexane and subjected to gas liquid chromatography (GLC) or
GLC/mass spectrometry (GLC/MS), as described previously [24]. UV
absorption spectra of lipid extracts were measured on a U-3210 spec-
trophotometer (Hitachi).
2.7. Measurement of sterol C-24(28) reductase activity
Enzymatic activity of Erg4p in yeast subcellular fractions of wild-
type and erg4 mutant cells was analyzed by measuring the conversion
of ergosta-5,7,22,24(28)-tetraen-3L-ol to ergosterol. The assay is based
on the method described by Neal and Parks [25] and was performed
with several modi¢cations. The standard assay mixture with a total
volume of 1 ml contained 1 Wmol NADPH, 20.5 Wmol EDTA and 100
nmol ergosta-5,7,22,24(28)-tetraen-3L-ol substrate (from a stock solu-
tion in ethanol, see below) in 0.1 M Tris^HCl, pH 7.5. The reaction
was started by adding 0.5 mg protein of various subcellular fractions;
incubations were carried out at 28‡C. Samples of 100 Wl were taken at
0, 0.5, 1 and 2 h, and lipids were extracted in 4 ml chloroform/meth-
anol (2:1; v/v) for 1 h. Lipid extracts were washed with 1 ml of
0.034% MgCl2 and 1 ml of methanol/water/chloroform (48:47:3,
v/v). The organic phase was dried under a stream of nitrogen and
samples were taken up in 0.75 ml methanol, 0.5 ml of 0.5% pyrogallol
and 0.5 ml of 60% KOH, and heated for 2 h at 85‡C to hydrolyze
steryl esters. Hydrolysates were extracted three times with 3 ml light
petroleum each, and the organic phases were combined and taken to
dryness. Lipids were dissolved in 50 Wl cyclohexane and subjected to
GLC (see above). Authentic ergosterol (Sigma) was used as a stan-
dard. Relative retention times of sterols were as described previously
[26^28]. The activity of sterol C-24(28) reductase was estimated based
on the increase of the amount of ergosterol.
For preparation of ergosta-5,7,22,24(28)-tetraen-3L-ol the erg4 de-
letion strain DZW244 was cultivated in synthetic medium without
ergosterol for 24 h, harvested and treated with methanol^KOH as
Fig. 2. Primers used for the construction of the ERG4^EGFP.
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described above. Lipids extracted with light petroleum were applied to
a column (20U1 cm) ¢lled with silica gel 60 (corn diameter 0.063^0.2
mm; Merck, Darmstadt, Germany). The solvent system used for the
elution of lipids was a gradient of light petroleum/diethylether starting
at a ratio of 70:30 with increasing amounts of diethylether. Fractions
of 1 ml were collected, and samples containing ergosta-5,7,22,24(28)-
tetraen-3L-ol were combined and dried under nitrogen. The resulting
product was dissolved in a small volume of cyclohexane and quanti-
¢ed by GLC with ergosterol (Sigma) as a standard.
2.8. Miscellaneous methods
Protein was quanti¢ed by the method of Lowry et al. [29] using
bovine serum albumin as a standard. Sodium dodecylsulfate poly-
acrylamide gel electrophoresis (SDS^PAGE) was carried out by the
method of Laemmli [30]. Western blot analysis was performed as
described by Haid and Suissa [31], and immunoreactive proteins
were detected by ELISA using rabbit antisera as the ¢rst and goat
anti-rabbit IgG linked to peroxidase or phosphatase as the second
antibody.
Fluidity of the plasma membrane was determined in vitro by mea-
suring the £uorescence anisotropy of TMA^DPH (trimethylammo-
nium^diphenylhexatriene) [32].
3. Results and discussion
3.1. Phenotypic analysis of an erg4 null mutant
Sterol C-24(28) reductase, Erg4p, catalyzes the ¢nal step in
the ergosterol biosynthetic pathway in yeast. Deletion of
ERG4 resulted in an accumulation of ergosta-5,7,22,24(28)-
tetraen-3L-ol up to 90% of total sterols, con¢rming previous
¢ndings by Lai et al. [8]. Since erg4 mutants lack detectable
levels of ergosterol it can be assumed that Erg4p is the only
sterol C-24(28) reductase present in yeast.
Ergosterol is a main constituent of the yeast plasma mem-
brane and is known to a¡ect membrane permeability, £uidity
and activity of membrane-bound proteins [1^4,33]. Thus,
changes of the sterol composition can be expected to a¡ect
certain properties of the plasma membrane. In the plasma
membrane of the erg4 mutant, ergosterol is completely re-
placed by ergosta-5,7,22,24(28)-tetraen-3L-ol (Table 1).
Although this sterol precursor is structurally highly related
to ergosterol, distinct phenotypic defects were observed with
the erg4 mutant indicating that ergosta-5,7,22,24(28)-tetraen-
3L-ol cannot fully replace ergosterol as a membrane compo-
nent.
As shown in Table 2 erg4 mutant cells are hypersensitive to
various drugs, such as cycloheximide, miconazole, terbina¢ne,
£uconazole and, to a lesser extent, nystatin and 4-nitroquino-
line. Lack of ergosterol in the plasma membrane of erg4 cells
may facilitate the import of certain drugs. This e¡ect, how-
ever, cannot be simply explained by an alteration of the mem-
brane £uidity: anisotropy measurements using a TMA^DPH
chromophore, which was incorporated into the plasma mem-
brane, revealed no di¡erences in chromophore mobility be-
tween erg4 mutant and wild-type (data not shown). Alterna-
tively, erg4 mutants may become more sensitive to drugs due
to a less e⁄cient e¥ux of these components mediated by
membrane-bound pumps of the multidrug resistance family.
Some of these transporters [34] may require ergosterol for
optimum activity although such a dependence has not yet
been systematically tested.
Increased sensitivity of erg4 mutant strains to the pore
forming macrolide antibiotic nystatin (see Table 2) is an in-
teresting phenomenon and suggests that this drug can interact
with ergosta-5,7,22,24(28)-tetraen-3L-ol in a similar way as
described previously for ergosterol to exert its growth inhib-
itory activity [35]. In contrast, other mutants with defects in
ergosterol biosynthesis, such as erg6, erg3 and erg5, which
accumulate sterols that are structurally more distant from
ergosterol, are nystatin-resistant [36]. Sterols accumulating in
these strains obviously fail to form complexes with the drug as
proposed for ergosterol.
As shown in Fig. 3, growth of erg4 mutants in two di¡erent
genetic backgrounds is drastically reduced in the presence of
brefeldin A. This fungal metabolite inhibits the exchange of
ADP ribosylation factor-bound GDP for GTP by a Golgi-
Table 1
Sterol composition of plasma membranes of an erg4 deletion strain
(DZW244) and the corresponding wild-type (W303)
Total sterols (%)
Wild-type erg4
Ergosterol 89.5 ND
Ergosta-5,7,22,24(28)-tetraen-3L-ol ND 89.0
Fecosterol 0.8 ND
Ergosta-5,7,24-trien-3L-ol 5.2 6.2
Episterol 1.2 1.0
Squalene 1.3 1.0
Zymosterol 0.9 0.3
Lanosterol 0.7 1.0
Others 0.4 1.5
ND, not detectable. Values were obtained from two independent es-
timations with a deviation of þ 5%.
Table 2
Sensitivity of the erg4 mutant to various reagents
Reagent Minimal inhibitory concentration
Wild-type erg4
Cycloheximide 1 Wg/ml 0.05 Wg/ml
Miconazole 0.05 Wg/ml 0.01 Wg/ml
Fluconazole 20 Wg/ml 2 Wg/ml
Terbina¢ne 100 Wg/ml 10 Wg/ml
4-Nitroquinoline 0.5 Wg/ml 0.25 Wg/ml
Nystatin 5 Wg/ml 2 Wg/ml
SDS 0.02% 0.0025%
Fig. 3. Growth inhibition of erg4 and erg6 deletion strains by bre-
feldin A. Exponential phase cells were spotted at densities of 1031,
1032, 1033, and 1034 onto YPD media plates without or with bre-
feldin A (50 Wg/ml and 100 Wg/ml) and incubated for 3 days at
30‡C.
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associated guanine nucleotide exchange protein [37,38] and
thus disrupts the Golgi apparatus and the £ux of secretory
proteins [39]. Whereas wild-type yeast cells are resistant
against more than 100 Wg/ml brefeldin A, mutants lacking
the ERG6 gene are highly susceptible to this drug (Fig. 3,
[40]). For this reason erg6 mutants have been widely used
for studies involving brefeldin A inhibition. Here we show
that mutants lacking ERG4 are as sensitive to brefeldin A
as erg6 mutant cells and may thus be used as an alternative
model system to study brefeldin A action in vivo with the
advantage of a less altered membrane sterol composition.
The erg4 deletion strain is also highly sensitive to SDS
(Table 2). Wild-type cells are able to tolerate 8^10-fold higher
concentrations of this ionic detergent compared to the erg4
mutant, whereas non-ionic detergents such as Brij 58 or Tri-
ton X-100 had similar e¡ects on mutant and wild-type (data
not shown). SDS may penetrate the plasma membrane of the
mutant more easily than that of wild-type, which, however, is
not due to an increased osmo-sensitivity of the mutant, since
erg4 cells grow like wild-type in the presence of 1 M sorbitol
(data not shown).
As shown in Table 3 the erg4 mutant is also more sensitive
to various divalent cations than wild-type. Resistance to diva-
lent cations is often conferred by membrane ATPases which
serve as pumps to protect cells from toxic compounds, or by
oxidoreductases which are responsible for detoxi¢cation [41].
These membrane-associated activities may be altered in the
mutant due to lack of ergosterol and/or accumulation of its
precursor.
3.2. Localization of Erg4p
At least three enzymes of the ergosterol biosynthetic path-
way, namely Erg1p, Erg6p and Erg7p [11^13], are dually lo-
cated both in the endoplasmic reticulum and in lipid particles.
It was suggested that lack or paucity of transmembrane span-
ning domains is the reason for a preferred occurrence of these
proteins in the membrane monolayer which surrounds lipid
particles [13]. In contrast to the above mentioned enzymes,
Erg4p contains eight transmembrane regions and is thus pre-
dicted to be embedded in a bilayer membrane. Indeed, highest
activity of Erg4p had previously been found in a 25 000Ug
membrane pellet [25].
To identify the subcellular localization of Erg4p in more
detail we tested isolated subcellular fractions for sterol
C-24(28) reductase activity by analyzing the conversion of
ergosta-5,7,22,24(28)-tetraen-3L-ol to ergosterol. The only sig-
ni¢cant activity (0.32 nmol/min mg) was found in the
40 000Ug microsomal fraction, corresponding largely to en-
doplasmic reticulum membranes. The enrichment factor of 7
over the homogenate for Erg4p re£ects the enrichment of
typical components of the endoplasmic reticulum [17]. Other
subcellular fractions such as lipid particles, mitochondria, vac-
uoles, and the plasma membrane were devoid of Erg4p activ-
ity.
Subcellular localization of Erg4p as determined by subcel-
lular fractionation of yeast cells was con¢rmed in vivo using a
C-terminal fusion of Erg4p to EGFP. The Erg4p^EGFP hy-
brid was expressed under the control of a heterologous
MET25p promoter in an erg4 mutant background, and visu-
alized by confocal laser scanning microscopy. Under dere-
pressing conditions, i.e. in the absence of methionine, the
fusion protein fully restored synthesis of ergosterol in the
erg4 mutant strain as determined by GLC analysis of total
cellular lipids, suggesting that the fusion protein was indeed
functional. Immunoblots of a homogenate that was prepared
from transformants expressing Erg4p^EGFP using GFP-spe-
ci¢c antibody unveiled a fusion protein of the predicted mass
of 86 kDa (56 kDa for Erg4p and 30 kDa for GFP).
Fluorescence microscopy of yeast transformants grown
under derepressing conditions demonstrates that Erg4p^
EGFP is localized to the endoplasmic reticulum (Fig. 4).
GFP £uorescence was observed around the nucleus and in
proximity to the cell periphery, which is typical of endoplas-
mic reticulum-resident proteins. Thus, based on activity mea-
surements in subcellular fractions in vitro and by £uorescence
microscopy in vivo, Erg4p is a component of the endoplasmic
reticulum in yeast, and is clearly absent from lipid particles.
3.3. Conclusions
As a consequence of the localization of Erg4p, sterol
C-24(28) reductase, which catalyzes the ¢nal step in the ergo-
sterol biosynthetic pathway in yeast, in the endoplasmic retic-
ulum this compartment must be regarded as the origin of
ergosterol, despite the fact that certain intermediate steps of
the pathway may also occur in lipid particles. Ergosterol syn-
Table 3
Cation sensitivity of the erg4 mutant
Cation Minimal inhibitory concentration (mM)
Wild-type erg4
Ca2 s 100 75
Mg2 s 200 75
Zn2 7.5 2.5
Mn2 20 10
Cu2 s 5 2.5
Cations were added to solid media at the indicated concentrations
as chlorides.
Fig. 4. Visualization of an Erg4p^EGFP fusion protein by £uores-
cence microscopy in vivo. The ERG4^EGFP hybrid was constructed
as described in Section 2. Expression of the fusion protein was in-
duced for 4 h in media lacking methionine. Left panel: GFP £uo-
rescence (single confocal section; 512U512 pixel; 4U line averaging
mode); right panel: DIC (di¡erential interference contrast) image of
the respective cells. Bar represents 10 Wm.
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thesized in the endoplasmic reticulum is transported to its
destinations, mainly to the plasma membrane where it occurs
in the highest concentrations, presumably via the secretory
pathway (H. Pichler, unpublished observations). The contri-
bution to sterol synthesis in vivo of Erg1p, Erg6p and Erg7p
located to lipid particles remains to be shown.
Another important consequence of the presence of sterol
C-24(28) reductase in the endoplasmic reticulum is that ergo-
sterol, the product formed by Erg4p, can be immediately me-
tabolized to ergosteryl esters in situ without prior transloca-
tion to another organelle/membrane system. Both steryl ester
synthases of the yeast, Are1p and Are2p [42,43], are also
components of the endoplasmic reticulum [24]. Interestingly,
steryl esters formed by these two enzymes are barely detect-
able in the endoplasmic reticulum and are exclusively stored
in lipid particles, which suggests rapid and e⁄cient interorga-
nelle translocation of these compounds in vivo. Furthermore,
only about 50% of steryl esters in lipid particles are derivatives
of ergosterol, whereas the other half contain sterol precursors.
Thus, steryl ester synthases may interact with several sterol
biosynthetic enzymes in the endoplasmic reticulum and thus
remove intermediates from the pathway by esteri¢cation and
subsequent storage in lipid particles. The presence of sterol
intermediates in esteri¢ed form in lipid particles as well as
some key enzymes of sterol synthesis, such as Erg1p, Erg6p
and Erg7p, suggests a depot function for lipid particles in
regulating the £ux through the ergosterol biosynthetic path-
way at the level of both enzymes and intermediate substrates.
Indeed, during the early exponential growth phase [44] or
upon starvation for sterols in the presence of metabolic inhib-
itors [45], sterols are mobilized from lipid particles and pre-
cursors are converted to ergosterol. Proteins involved in this
translocation process, enzymes responsible for steryl ester
cleavage and factors governing regulation of the interaction
between lipid particles and the endoplasmic reticulum, how-
ever, remain to be identi¢ed.
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